Novartis CEO warns that data on Covid-19 drugs is missing
Business was good for Novartis in the first quarter of the year.
Keystone / Georgios Kefalas
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
This content was published on
2 minutes
SDA-Keystone/ac
Español
es
Novartis: faltan datos sobre fármacos anticoronavirus
Clinical studies that are properly conducted are necessary to really determine the benefit of drugs, Narasimhan told the Reuters news agency on Tuesday. Only a few drugs had met the standards so far, he said.
The Swiss pharmaceutical company has initiated a clinical study with the anti-malarial drug hydroxychloroquine. Last month he told the Swiss media that pre-clinical studies in animals as well as the first data from clinical studies showed that hydroxychloroquine kills the coronavirus. While the therapy is not yet available, Narasimhan hinted that the first study results could be available in summer.
The Basel-based company also announced its first quarter results on Tuesday, reporting a 11% increase in net sales and a turnover of $12.28 billion (CHF12 billion). Novartis says it has managed to weather the coronavirus storm to keep production facilities going.
“Our operations and product demand remain very stable and strong. Mitigating actions helped to ensure minimal disruption to supply chain and ability to meet forward purchasing demand,” according to a company statement.
Forward purchasing and lower spending meant that Novartis made an extra $400 million due to the coronavirus pandemic in the first quarter. However, it is likely that these gains will be reversed over the remainder of 2020, the company cautioned.
More
More
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
Consumer prices picked up again in June in Switzerland, after briefly dipping into negative territory the previous month.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.